Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 214683, 8 pages
http://dx.doi.org/10.1155/2015/214683
Research Article

Inhibitory Effect of a Novel Antirheumatic Drug T-614 on the IL-6-Induced RANKL/OPG, IL-17, and MMP-3 Expression in Synovial Fibroblasts from Rheumatoid Arthritis Patients

Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China

Received 8 May 2014; Revised 25 October 2014; Accepted 28 October 2014

Academic Editor: James C. C. Wei

Copyright © 2015 Yu Wei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Y. Yoon, E. G. Lee, H. Lee et al., “Kaempferol inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs,” International Journal of Molecular Medicine, vol. 32, no. 4, pp. 971–977, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. P. P. C. Souza and U. H. Lerner, “The role of cytokines in inflammatory bone loss,” Immunological Investigations, vol. 42, no. 7, pp. 555–622, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Li, I. Sarosi, X. Q. Yan et al., “RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 4, pp. 1566–1571, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. H.-Y. Lee, H.-S. Jeon, E.-K. Song et al., “CD40 ligation of rheumatoid synovial fibroblasts regulates RANKL-mediated osteoclastogenesis: evidence of NF-κB-dependent, CD40-mediated bone destruction in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 54, no. 6, pp. 1747–1758, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. X.-F. Li, H. Xu, Y.-J. Zhao et al., “Icariin augments bone formation and reverses the phenotypes of osteoprotegerin-deficient mice through the activation of WNT/β-catenin-BMP signaling,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 652317, 13 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. J. L. Nam, K. L. Winthrop, R. F. van Vollenhoven et al., “Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 976–986, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Smolen, D. Aletaha, M. Koeller, M. H. Weisman, and P. Emery, “New therapies for treatment of rheumatoid arthritis,” The Lancet, vol. 370, no. 9602, pp. 1861–1874, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Gaujoux-Viala, S. Paternotte, B. Combe, and M. Dougados, “Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort,” Rheumatology, vol. 51, no. 9, Article ID kes135, pp. 1648–1654, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Y. Sun, Y. Su, L. M. Ren, L. Han, and Z. G. Li, “Therapeutic effect and impact on cytokine production by methotrexate in rheumatoid arthritis,” Beijing Da Xue Xue Bao, vol. 38, no. 4, pp. 356–359, 2006. View at Google Scholar
  10. S. Revu, P. Neregård, E. af Klint, M. Korotkova, and A. I. Catrina, “Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate,” Arthritis Research and Therapy, vol. 15, no. 6, article R205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. L.-J. Lu, C.-D. Bao, M. Dai et al., “Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate,” Arthritis Care and Research, vol. 61, no. 7, pp. 979–987, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Du, L.-J. Lü, Q. Fu et al., “T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis,” Arthritis Research and Therapy, vol. 10, no. 6, article R136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Tanaka, H. Kawasaki, K. Kurata, Y. Aikawa, Y. Tsukamoto, and T. Inaba, “T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts,” The Japanese Journal of Pharmacology, vol. 67, no. 4, pp. 305–314, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Nakajima, M. Hakoda, H. Yamanaka, N. Kamatani, and S. Kashiwazaki, “Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 55, no. 4, pp. 237–242, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Hashizume, N. Hayakawa, and M. Mihara, “IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17,” Rheumatology, vol. 47, no. 11, pp. 1635–1640, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Nistala, H. Moncrieffe, K. R. Newton, H. Varsani, P. Hunter, and L. R. Wedderburn, “Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers,” Arthritis and Rheumatism, vol. 58, no. 3, pp. 875–887, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Wen, Y. Li, M. Wu et al., “Therapeutic effects of a novel tylophorine analog, NK-007, on collagen-induced arthritis through suppressing tumor necrosis factor α production and Th17 cell differentiation,” Arthritis and Rheumatism, vol. 64, no. 9, pp. 2896–2906, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Du, L.-J. Lü, J.-L. Teng, N. Shen, P. Ye, and C.-D. Bao, “T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro,” International Immunopharmacology, vol. 13, no. 1, pp. 54–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. P. C. Heinrich, I. Behrmann, S. Haan, H. M. Hermanns, G. Müller-Newen, and F. Schaper, “Principles of interleukin (IL)-6-type cytokine signalling and its regulation,” Biochemical Journal, vol. 374, no. 1, pp. 1–20, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Nakano, Y. Okada, K. Saito, and Y. Tanaka, “Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts,” Arthritis and Rheumatism, vol. 50, no. 8, pp. 2450–2458, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-J. Yun, E.-G. Lee, S.-I. Lee, H.-J. Chae, and W.-H. Yoo, “Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-α,” Rheumatology International, vol. 29, no. 10, pp. 1161–1168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Onal, J. Xiong, X. Chen et al., “Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss,” Journal of Biological Chemistry, vol. 287, no. 35, pp. 29851–29860, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Fujii, H. Kitaura, K. Kimura, Z. W. Hakami, and T. Takano-Yamamoto, “IL-4 inhibits TNF-α-mediated osteoclast formation by inhibition of RANKL expression in TNF-α-activated stromal cells and direct inhibition of TNF-α-activated osteoclast precursors via a T-cell-independent mechanism in vivo,” Bone, vol. 51, no. 4, pp. 771–780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Riegel, T. Maurer, B. Prior et al., “Human polymorphonuclear neutrophils express RANK and are activated by its ligand, RANKL,” European Journal of Immunology, vol. 42, no. 4, pp. 975–981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Tunyogi-Csapo, K. Kis-Toth, M. Radacs et al., “Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: Fibroblast-mediated pathologic bone resorption,” Arthritis and Rheumatism, vol. 58, no. 8, pp. 2397–2408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Glehr, M. Breisach, S. Walzer et al., “The Influence of resveratrol on the synovial expression of matrix metalloproteinases and receptor activator of NF-κB ligand in rheumatoid arthritis fibroblast-like synoviocytes,” Zeitschrift fur Naturforschung C: Journal of Biosciences, vol. 68, no. 7-8, pp. 336–342, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Bucay, I. Sarosi, C. R. Dunstan et al., “Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification,” Genes and Development, vol. 12, no. 9, pp. 1260–1268, 1998. View at Publisher · View at Google Scholar · View at Scopus